Holen Sie sich die Stockscreener-App
27.91
1.06%
0.325
Schlusskurs vom Vortag:
$27.58
Offen:
$27.44
24-Stunden-Volumen:
306.81K
Relative Volume:
0.19
Marktkapitalisierung:
$4.80B
Einnahmen:
$1.10B
Nettoeinkommen (Verlust:
$375.65M
KGV:
12.71
EPS:
2.1963
Netto-Cashflow:
$113.59M
1W Leistung:
-3.66%
1M Leistung:
-4.58%
6M Leistung:
+23.44%
1J Leistung:
+12.21%
1-Tages-Spanne:
$27.40
$27.95
1-Wochen-Bereich:
$27.10
$29.07
52-Wochen-Spanne:
$19.69
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
27.87 | 4.75B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
522.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.41 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-23 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Acadia Pharma GLP-1 Receptor Agonists Weight Management Diabetes Treatments *zLHGd49l0* - akhmetovfoundation.org
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com India
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains As Fundamentals Improve - Kalkine Media
The Technical Signals Behind (ACAD) That Institutions Follow - Stock Traders Daily
Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative? - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Trading At A Discount As DAYBU Wins EU Approval? - Sahm
Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Deutsche Bank raises Acadia Pharma price target after EU approval of Daybu for Rett syndrome. - Pluang
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $40 - Moomoo
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40 - Moomoo
Acadia Gets European Commission Nod for Daybu in Rett Syndrome - Eastern Progress
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe - pharmaphorum
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union - Via TT
ACADIA (ACAD) Close: Advances 1.05% to $29.34; Technical View: the Session Ends Within the Reported Technical Boundaries on the DayMarket Leader Picks - vinanet.vn
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA (ACAD) Earnings Report: EPS Clears the Reported Estimate at the Close; Closing Reaction: The Stock Gains 1.09% in the Current UpdateSlow Growth Warning - vinanet.vn
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36 - Moomoo
Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st
UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia
ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus
UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - MarketBeat
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - MarketBeat
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):